Advances in haploidentical stem cell transplantation for hematologic malignancies

Area of Science:

• Immunology
• Hematology
• Transplantation Science

Background:

• Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is advancing with alternative donor sources.
• Haploidentical HSCT (haplo-HSCT) from family donors presents unique challenges in managing alloreactivity.
• Graft-versus-host disease (GVHD) remains a significant complication in allo-HSCT.

Purpose of the Study:

• To review current strategies for overcoming bidirectional alloreactivity in haploidentical HSCT.
• To discuss various approaches for GVHD prophylaxis in the context of haplo-HSCT.
• To explore emerging experimental strategies and donor selection considerations for haplo-HSCT.

Main Methods:

• Discussion of ex vivo T-cell-depleted grafts with high CD34(+) cell doses.
• Analysis of unmanipulated T-cell-replete grafts with intensive immunosuppression or post-transplantation cyclophosphamide.
• Review of novel strategies including selective T-cell depletion, antigen-specific T-cell infusions, and regulatory T-cell therapy.

Main Results:

• Ex vivo T-cell-depleted grafts may obviate the need for post-transplant immunosuppression for GVHD prophylaxis.
• Intensive immunosuppression or post-transplantation cyclophosphamide are key in T-cell-replete haplo-HSCT strategies.
• Experimental approaches show promise in refining GVHD management and enhancing graft-versus-leukemia effects.

Conclusions:

• Multiple strategies exist to manage alloreactivity and GVHD in haplo-HSCT.
• The choice of strategy depends on balancing graft-versus-host and graft-versus-leukemia responses.
• Further research into novel cell-based therapies and donor selection is crucial for optimizing haplo-HSCT outcomes.